Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis
Asherman’s Syndrome (AS) is an uncommon, acquired, and refractory gynecological disorder. Current treatment was still limited, and stem cell-based therapy has been proposed as a novel strategy for management of AS. Here, we conducted a meta-analysis of self-controlled clinical trials to assess the e...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2020/8820538 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568476839968768 |
|---|---|
| author | Yiming Zhao Qifan Luo Xiao Zhang Yafei Qin Jingpeng Hao Dejun Kong Hongda Wang Guangming Li Xiangying Gu Hao Wang |
| author_facet | Yiming Zhao Qifan Luo Xiao Zhang Yafei Qin Jingpeng Hao Dejun Kong Hongda Wang Guangming Li Xiangying Gu Hao Wang |
| author_sort | Yiming Zhao |
| collection | DOAJ |
| description | Asherman’s Syndrome (AS) is an uncommon, acquired, and refractory gynecological disorder. Current treatment was still limited, and stem cell-based therapy has been proposed as a novel strategy for management of AS. Here, we conducted a meta-analysis of self-controlled clinical trials to assess the effectiveness and safety of stem cell-based therapy in Asherman syndrome patients who have failed in conventional treatment. We systematically searched PubMed, Embase, Cochrane, and Web of Science database (published up to October 3, 2020). Our main evaluation outcomes were menses improvement, endometrial thickness changes, pregnancy outcome, and side effects. All analyses were performed by using RevMan5.4 software. 427 studies were identified, eight of which were eligible and included in our analysis. Stem cell combined hormone therapy achieved a higher likelihood of improving menstruation (risk ratio [RR] 22.43, 95% CI: 8.03 to 62.68, P<0.00001), an enhancement of pregnancy outcome (risk ratio [RR] 11.1, 95% CI: 3.58 to 34.38, P<0.0001), and a mean increase of 3-month endometrial thickness (standardized mean difference [SMD] 2.43, 95% CI: 1.72 to 3.13, P<0.00001). Subgroup analysis also indicated that 6-month and 9-month endometrial thickness increased significantly with the stem cell-based treatment. Moreover, no obvious and severe adverse reactions were observed during the process of stem cell therapy. There were 3 patients (3.57%) reported with lost appetite, mild gastritis, vomiting, or abdominal cramps, whereas, these symptoms relieved subsequently. This meta-analysis systematically reviewed and synthesized the outcomes of stem cell-based therapy in treating Asherman syndrome, which suggest that stem cell and hormone combination therapy was safe and more effective in improving menstruation duration, pregnancy outcome, and endometrial thickness. However, further trials with large sample sizes are needed to establish more solid evidence for administrating this therapy in clinic. |
| format | Article |
| id | doaj-art-16faa10428474abc8190fe539513f578 |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-16faa10428474abc8190fe539513f5782025-02-03T00:58:52ZengWileyStem Cells International1687-966X1687-96782020-01-01202010.1155/2020/88205388820538Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-AnalysisYiming Zhao0Qifan Luo1Xiao Zhang2Yafei Qin3Jingpeng Hao4Dejun Kong5Hongda Wang6Guangming Li7Xiangying Gu8Hao Wang9Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of General Surgery, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Anorectal Surgery, The Second Hospital of Tianjin Medical University, Tianjin, ChinaDepartment of General Surgery, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of General Surgery, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of General Surgery, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of General Surgery, Tianjin Medical University General Hospital, Tianjin, ChinaAsherman’s Syndrome (AS) is an uncommon, acquired, and refractory gynecological disorder. Current treatment was still limited, and stem cell-based therapy has been proposed as a novel strategy for management of AS. Here, we conducted a meta-analysis of self-controlled clinical trials to assess the effectiveness and safety of stem cell-based therapy in Asherman syndrome patients who have failed in conventional treatment. We systematically searched PubMed, Embase, Cochrane, and Web of Science database (published up to October 3, 2020). Our main evaluation outcomes were menses improvement, endometrial thickness changes, pregnancy outcome, and side effects. All analyses were performed by using RevMan5.4 software. 427 studies were identified, eight of which were eligible and included in our analysis. Stem cell combined hormone therapy achieved a higher likelihood of improving menstruation (risk ratio [RR] 22.43, 95% CI: 8.03 to 62.68, P<0.00001), an enhancement of pregnancy outcome (risk ratio [RR] 11.1, 95% CI: 3.58 to 34.38, P<0.0001), and a mean increase of 3-month endometrial thickness (standardized mean difference [SMD] 2.43, 95% CI: 1.72 to 3.13, P<0.00001). Subgroup analysis also indicated that 6-month and 9-month endometrial thickness increased significantly with the stem cell-based treatment. Moreover, no obvious and severe adverse reactions were observed during the process of stem cell therapy. There were 3 patients (3.57%) reported with lost appetite, mild gastritis, vomiting, or abdominal cramps, whereas, these symptoms relieved subsequently. This meta-analysis systematically reviewed and synthesized the outcomes of stem cell-based therapy in treating Asherman syndrome, which suggest that stem cell and hormone combination therapy was safe and more effective in improving menstruation duration, pregnancy outcome, and endometrial thickness. However, further trials with large sample sizes are needed to establish more solid evidence for administrating this therapy in clinic.http://dx.doi.org/10.1155/2020/8820538 |
| spellingShingle | Yiming Zhao Qifan Luo Xiao Zhang Yafei Qin Jingpeng Hao Dejun Kong Hongda Wang Guangming Li Xiangying Gu Hao Wang Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis Stem Cells International |
| title | Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
| title_full | Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
| title_fullStr | Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
| title_full_unstemmed | Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
| title_short | Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
| title_sort | clinical efficacy and safety of stem cell based therapy in treating asherman syndrome a system review and meta analysis |
| url | http://dx.doi.org/10.1155/2020/8820538 |
| work_keys_str_mv | AT yimingzhao clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT qifanluo clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT xiaozhang clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT yafeiqin clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT jingpenghao clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT dejunkong clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT hongdawang clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT guangmingli clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT xiangyinggu clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT haowang clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis |